Cocrystal Pharma Inc (COCP) 0.7176 $COCP
Nasopharyngitis (Common Cold) Pipeline Review, H2 2015 - 5 Companies & 11 Drug Profiles
M2 - Fri Sep 04, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jrkmc3/nasopharyngitis) has announced the addition of the "Nasopharyngitis (Common Cold) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Nasopharyngitis (Common Cold), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nasopharyngitis (Common Cold) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Charleston Laboratories, Inc. - Cocrystal Pharma, Inc. - Neos Therapeutics, Inc. - Orbis Biosciences, Inc. - Vernalis Plc Drug Profiles - (chlorpheniramine maleate codeine) - Antibody to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - CCP-05 - CCP-06 - CCP-07 - CCP-08 - CLAT-313 - guaifenesin ER - Small Molecule for Cough and Cold - Small Molecule to Inhibit MAPK13 for Asthma and Cold - Small Molecules to Inhibit RNA Dependent RNA Polymerase for Common Cold For more information visit http://www.researchandmarkets.com/research/jr...haryngitis
NEOS: 23.30 (+1.34)
H5N1 Infection (Avian Influenza) Pipeline Review 2015 - 42 Companies & 59 Drug Profiles
M2 - Fri Jul 31, 10:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/spx39q/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Akshaya Bio Inc. - AlphaVax, Inc. - Antigen Express, Inc. - Aphios Corporation - Aprogen, Inc. - BioDiem Ltd - CEL-SCI Corporation - Cocrystal Pharma, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Gemmus Pharma Inc. - GlaxoSmithKline Plc - Green Cross Corporation - Hemispherx Biopharma, Inc. - iBio, Inc. - Immunovaccine, Inc. - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - Kineta, Inc. - Medicago Inc. - Medigen Biotechnology Corporation - Microgen Scientific Industrial Company for Immunobiological Medicines - Myelo Therapeutics GmbH - NanoBio Corporation - Nanotherapeutics, Inc. - NanoViricides, Inc. - NewLink Genetics Corporation - Novartis AG - OPKO Health, Inc. - PaxVax - PDS Biotechnology Corporation - PeptiDream Inc. - Protein Sciences Corporation - REPLICor Inc. - SIGA Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/sp..._infection
JNJ: 92.93 (+0.21), INO: 7.34 (+0.23), EBS: 32.58 (+0.39), CVM: 0.64 (-0.02), OPK: 10.09 (-0.46), NLNK: 51.03 (+1.84), IBIO: 0.70 (-0.01), NNVC: 1.02 (-0.02), GSK: 40.26 (+0.02), NVS: 96.55 (+0.28)
IDI Management Fires Back Against Blog Post
at The Street - Wed Jul 22, 11:32AM CDT
Executives say investor Philip Frost supports them and the company.
YHOO: 31.43 (+0.28), IDI: 6.52 (+0.17), EFX: 98.00 (+0.14)
Cocrystal Pharma Names Walt Addison Linscott, Esq. New General Counsel and Corporate Secretary
Marketwired - Wed Jul 15, 8:25AM CDT
Cocrystal Pharma, Inc. (OTCQB:COCP), a company focused on developing novel antiviral therapeutics for human diseases, announced today the appointment of Walt Addison Linscott, Esq. as General Counsel and Corporate Secretary.
ABT: 43.41 (+0.29)
Cocrystal Pharma to Present at Jefferies 2015 Global Healthcare Conference
Marketwired - Thu May 28, 8:27AM CDT
Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, announced today that it will be presenting at the Jefferies 2015 Global Healthcare Conference on Thursday, June 4, 2015 from 12:30 p.m. to 1:00 p.m. at the Grand Hyatt in New York, New York.
Global Hepatitis C Pipeline Report 2015 - 103 Companies & 251 Drug Profiles
M2 - Wed May 20, 4:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/96rn9k/hepatitis_c) has announced the addition of the "Hepatitis C - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis C and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 30 of the 100 Companies - 3-V Biosciences, Inc. - AbbVie Inc. - Achillion Pharmaceuticals, Inc. - Adaptimmune Limited - AiCuris GmbH & Co. KG - AIMM Therapeutics B.V. - Akshaya Bio Inc. - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amarna Therapeutics B.V. - American Gene Technologies International Inc. - Anacor Pharmaceuticals, Inc. - ARA Healthcare Pvt. Ltd. - Arrowhead Research Corporation - Ascendis Pharma A/S - Astex Pharmaceuticals, Inc. - Biogenomics Limited - BioLineRx, Ltd. - Bionor Pharma ASA - Biotest AG - Biotron Limited - Bolder Biotechnology, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Chiasma, Inc. - Chugai Pharmaceutical Co., Ltd. - Cocrystal Pharma, Inc. - Conatus Pharmaceuticals Inc. - Crucell N.V. - Debiopharm International S.A. For more information visit http://www.researchandmarkets.com/research/96...epatitis_c
ASND: 20.60 (+0.05), ARWR: 6.40 (+0.68), ACHN: 7.77 (+0.04), CNAT: 4.44 (+0.10), ANAC: 141.14 (+1.10), ABBV: 59.35 (-0.23), BMY: 59.22 (+0.47), CELGZ: 1.93 (+0.07)
Solid Pipeline and Big Player Backing: Cocrystal Pharma Analyst Report Issued by BrokerBank Securities, Inc.
PR Newswire - Mon Apr 27, 6:00AM CDT
Cocrystal Pharma Inc. (OTCQB: COCP) a Washington-State based pharmaceutical company working to develop antiviral therapeutics as treatments for serious and/or chronic viral diseases, expects to begin clinical studies on several of its antiviral therapeutic treatments in 2015. The company has several drugs in various stages of development for the treatment of Hepatitis C, Influenza, Norovirus, Dengue Fever and others.
InsiderInsights.com Daily Round Up 4/23/15: GE, OMN, COCP, AGCO
InsiderInsights - at Seeking Alpha - Fri Apr 24, 7:53AM CDT
STFC: 24.26 (+0.13), GE: 24.95 (+0.27), OMN: 5.72 (-0.16), AGCO: 47.40 (-1.06), SAM: 215.71 (+2.31), AMGN: 153.21 (+0.07), ILMN: 206.41 (+6.46), NXRT: 13.81 (+0.40), BDCV: 4.69 (-0.09), MPWR: 50.62 (+0.93), WCIC: 24.79 (-0.58), ADS: 253.63 (+1.89), KMX: 60.21 (+0.39), SVVC: 9.40 (-0.03), ALNY: 107.70 (+1.94), GRPN: 4.22 (+0.01), UCTT: 6.29 (-0.12)
Cocrystal Pharma - Overhyped Biotech Or The Next Pharmasset?
Greg Buch - at Seeking Alpha - Tue Apr 07, 10:19AM CDT
Opko and its CEO Dr. Phillip Frost Add MabVax to Their Portfolios
ACCESSWIRE - Mon Apr 06, 6:15PM CDT
CORAL GABLES, FL / ACCESSWIRE / April 6, 2015 / Holding companies invest in the securities of other companies all the time aiming to increase shareholder value. There are hits and there are misses, as with all investments. But Opko Health (NYSE: OPK) has been on such a hot streak in this game especially in the last few months that even relatively small deals deserve attention. Its latest move - both for Opko and for Frost's personal investment trust - is to be part of a $12M private placement into MabVax Therapeutics (OTCQB: MBVX).
OPK: 10.09 (-0.46), PFE: 32.97 (+0.35), JUNO: 41.58 (+1.15), NVCN: 6.23 (-0.29)
InsiderInsights.com Daily Round Up 3/27/15: COCP, GPRO, SJW, AGCO
InsiderInsights - at Seeking Alpha - Sun Mar 29, 12:55PM CDT
GPRO: 32.42 (-1.46), HCOM: 21.56 (+0.20), DPLO: 39.42 (+0.32), AGCO: 47.40 (-1.06), ENV: 30.09 (-0.44), LPI: 9.72 (-0.18), GOOG: 625.77 (+4.42), NOW: 73.60 (+0.94), ARMK: 31.69 (+0.43), JAZZ: 160.62 (-0.21), GLF: 7.39 (-0.38), SJW: 28.33 (+0.23), JGW: 5.34 (+0.17), ALCO: 42.01 (+0.80), FI: 16.43 (-0.09), CRM: 70.05 (+0.31)
Opko's Frost Inks Levon Deal with Israel's SciVac, a Hint for the Next Merger?
ACCESSWIRE - Fri Mar 20, 10:30AM CDT
NEW YORK, NY / ACCESSWIRE / March 20, 2015 / On September 11 last year, a little-known Israeli financial magazine called Globes came out with a report that Dr. Phillip Frost, Chairman and CEO of Opko Health (NYSE:OPK), and then Chairman of Teva Pharmaceuticals (NYSE:TEVA), was interested in moving a private Israeli biotech called SciVac, 45% owned by Opko, into a corporate shell and making it public.
OPK: 10.09 (-0.46), TEVA: 63.66 (+1.62)
Cocrystal Pharma announces changes in executive positions
M2 - Fri Mar 13, 7:15AM CDT
Pharmaceutical company Cocrystal Pharma (OTCQB:COCP) reported on Thursday that Dr Gary Wilcox will step down as its chief executive officer due to medical reasons.
Cocrystal Pharma to Appoint Jeffrey Meckler as Interim Chief Executive Officer
Marketwired - Thu Mar 12, 6:30AM CDT
Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, announced today that due to medical reasons, Dr. Gary Wilcox will step down as the current Chief Executive Officer. Mr. Jeffrey Meckler has been appointed as the Interim Chief Executive Officer of the Company effective with the filing of the Form 10-K, later this month. Dr. Wilcox will become the Vice Chairman of the Board of Directors and continue as a senior advisor to the company. Mr. Meckler will continue as a Director of the Company, and Dr. Raymond F. Schinazi will become the Chairman of the Board.
QLTI: 3.44 (unch), OPK: 10.09 (-0.46), PFE: 32.97 (+0.35)
Cocrystal Pharma to Present at Barclays Global Healthcare Conference on Thursday, March 12
Marketwired - Tue Mar 03, 8:24AM CST
Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, announced today that it will present at the Barclays 2015 Global Healthcare Conference on Thursday, March 12, 2015 at 8:00 AM ET at Loews Miami Beach Hotel in Miami, Florida. Dr. Raymond F. Schinazi, co-chairman of the Board of Directors of Cocrystal Pharma, will be presenting on behalf of the Company.
OPK: 10.09 (-0.46)
Nasopharyngitis (Common Cold) - Pipeline Review, H1 2015 - 11 Drug Profiles from 4 Companies
M2 - Mon Mar 02, 8:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/29q354/nasopharyngitis) has announced the addition of the "Nasopharyngitis (Common Cold) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Nasopharyngitis (Common Cold), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nasopharyngitis (Common Cold) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cocrystal Pharma, Inc. - Neos Therapeutics, Inc. - Orbis Biosciences, Inc. - Vernalis plc Drug Profiles - (chlorpheniramine codeine) - Antibody to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - CCP-01 - CCP-05 - CCP-06 - CCP-07 - CCP-08 - guaifenesin ER - Small Molecule for Cough and Cold - Small Molecule to Inhibit MAPK13 for Asthma and Cold - Small Molecules to Inhibit RNA Dependent RNA Polymerase for Common Cold For more information visit http://www.researchandmarkets.com/research/29...haryngitis
Nasopharyngitis (Common Cold) Pipeline Review, H2 2015 - 5 Companies & 11 Drug Profiles
M2 - Fri Sep 04, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jrkmc3/nasopharyngitis) has announced the addition of the "Nasopharyngitis (Common Cold) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Nasopharyngitis (Common Cold), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nasopharyngitis (Common Cold) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Charleston Laboratories, Inc. - Cocrystal Pharma, Inc. - Neos Therapeutics, Inc. - Orbis Biosciences, Inc. - Vernalis Plc Drug Profiles - (chlorpheniramine maleate codeine) - Antibody to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - CCP-05 - CCP-06 - CCP-07 - CCP-08 - CLAT-313 - guaifenesin ER - Small Molecule for Cough and Cold - Small Molecule to Inhibit MAPK13 for Asthma and Cold - Small Molecules to Inhibit RNA Dependent RNA Polymerase for Common Cold For more information visit http://www.researchandmarkets.com/research/jr...haryngitis
NEOS: 23.30 (+1.34)
H5N1 Infection (Avian Influenza) Pipeline Review 2015 - 42 Companies & 59 Drug Profiles
M2 - Fri Jul 31, 10:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/spx39q/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Akshaya Bio Inc. - AlphaVax, Inc. - Antigen Express, Inc. - Aphios Corporation - Aprogen, Inc. - BioDiem Ltd - CEL-SCI Corporation - Cocrystal Pharma, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Gemmus Pharma Inc. - GlaxoSmithKline Plc - Green Cross Corporation - Hemispherx Biopharma, Inc. - iBio, Inc. - Immunovaccine, Inc. - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - Kineta, Inc. - Medicago Inc. - Medigen Biotechnology Corporation - Microgen Scientific Industrial Company for Immunobiological Medicines - Myelo Therapeutics GmbH - NanoBio Corporation - Nanotherapeutics, Inc. - NanoViricides, Inc. - NewLink Genetics Corporation - Novartis AG - OPKO Health, Inc. - PaxVax - PDS Biotechnology Corporation - PeptiDream Inc. - Protein Sciences Corporation - REPLICor Inc. - SIGA Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/sp..._infection
JNJ: 92.93 (+0.21), INO: 7.34 (+0.23), EBS: 32.58 (+0.39), CVM: 0.64 (-0.02), OPK: 10.09 (-0.46), NLNK: 51.03 (+1.84), IBIO: 0.70 (-0.01), NNVC: 1.02 (-0.02), GSK: 40.26 (+0.02), NVS: 96.55 (+0.28)
IDI Management Fires Back Against Blog Post
at The Street - Wed Jul 22, 11:32AM CDT
Executives say investor Philip Frost supports them and the company.
YHOO: 31.43 (+0.28), IDI: 6.52 (+0.17), EFX: 98.00 (+0.14)
Cocrystal Pharma Names Walt Addison Linscott, Esq. New General Counsel and Corporate Secretary
Marketwired - Wed Jul 15, 8:25AM CDT
Cocrystal Pharma, Inc. (OTCQB:COCP), a company focused on developing novel antiviral therapeutics for human diseases, announced today the appointment of Walt Addison Linscott, Esq. as General Counsel and Corporate Secretary.
ABT: 43.41 (+0.29)
Cocrystal Pharma to Present at Jefferies 2015 Global Healthcare Conference
Marketwired - Thu May 28, 8:27AM CDT
Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, announced today that it will be presenting at the Jefferies 2015 Global Healthcare Conference on Thursday, June 4, 2015 from 12:30 p.m. to 1:00 p.m. at the Grand Hyatt in New York, New York.
Global Hepatitis C Pipeline Report 2015 - 103 Companies & 251 Drug Profiles
M2 - Wed May 20, 4:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/96rn9k/hepatitis_c) has announced the addition of the "Hepatitis C - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis C and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 30 of the 100 Companies - 3-V Biosciences, Inc. - AbbVie Inc. - Achillion Pharmaceuticals, Inc. - Adaptimmune Limited - AiCuris GmbH & Co. KG - AIMM Therapeutics B.V. - Akshaya Bio Inc. - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amarna Therapeutics B.V. - American Gene Technologies International Inc. - Anacor Pharmaceuticals, Inc. - ARA Healthcare Pvt. Ltd. - Arrowhead Research Corporation - Ascendis Pharma A/S - Astex Pharmaceuticals, Inc. - Biogenomics Limited - BioLineRx, Ltd. - Bionor Pharma ASA - Biotest AG - Biotron Limited - Bolder Biotechnology, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Chiasma, Inc. - Chugai Pharmaceutical Co., Ltd. - Cocrystal Pharma, Inc. - Conatus Pharmaceuticals Inc. - Crucell N.V. - Debiopharm International S.A. For more information visit http://www.researchandmarkets.com/research/96...epatitis_c
ASND: 20.60 (+0.05), ARWR: 6.40 (+0.68), ACHN: 7.77 (+0.04), CNAT: 4.44 (+0.10), ANAC: 141.14 (+1.10), ABBV: 59.35 (-0.23), BMY: 59.22 (+0.47), CELGZ: 1.93 (+0.07)
Solid Pipeline and Big Player Backing: Cocrystal Pharma Analyst Report Issued by BrokerBank Securities, Inc.
PR Newswire - Mon Apr 27, 6:00AM CDT
Cocrystal Pharma Inc. (OTCQB: COCP) a Washington-State based pharmaceutical company working to develop antiviral therapeutics as treatments for serious and/or chronic viral diseases, expects to begin clinical studies on several of its antiviral therapeutic treatments in 2015. The company has several drugs in various stages of development for the treatment of Hepatitis C, Influenza, Norovirus, Dengue Fever and others.
InsiderInsights.com Daily Round Up 4/23/15: GE, OMN, COCP, AGCO
InsiderInsights - at Seeking Alpha - Fri Apr 24, 7:53AM CDT
STFC: 24.26 (+0.13), GE: 24.95 (+0.27), OMN: 5.72 (-0.16), AGCO: 47.40 (-1.06), SAM: 215.71 (+2.31), AMGN: 153.21 (+0.07), ILMN: 206.41 (+6.46), NXRT: 13.81 (+0.40), BDCV: 4.69 (-0.09), MPWR: 50.62 (+0.93), WCIC: 24.79 (-0.58), ADS: 253.63 (+1.89), KMX: 60.21 (+0.39), SVVC: 9.40 (-0.03), ALNY: 107.70 (+1.94), GRPN: 4.22 (+0.01), UCTT: 6.29 (-0.12)
Cocrystal Pharma - Overhyped Biotech Or The Next Pharmasset?
Greg Buch - at Seeking Alpha - Tue Apr 07, 10:19AM CDT
Opko and its CEO Dr. Phillip Frost Add MabVax to Their Portfolios
ACCESSWIRE - Mon Apr 06, 6:15PM CDT
CORAL GABLES, FL / ACCESSWIRE / April 6, 2015 / Holding companies invest in the securities of other companies all the time aiming to increase shareholder value. There are hits and there are misses, as with all investments. But Opko Health (NYSE: OPK) has been on such a hot streak in this game especially in the last few months that even relatively small deals deserve attention. Its latest move - both for Opko and for Frost's personal investment trust - is to be part of a $12M private placement into MabVax Therapeutics (OTCQB: MBVX).
OPK: 10.09 (-0.46), PFE: 32.97 (+0.35), JUNO: 41.58 (+1.15), NVCN: 6.23 (-0.29)
InsiderInsights.com Daily Round Up 3/27/15: COCP, GPRO, SJW, AGCO
InsiderInsights - at Seeking Alpha - Sun Mar 29, 12:55PM CDT
GPRO: 32.42 (-1.46), HCOM: 21.56 (+0.20), DPLO: 39.42 (+0.32), AGCO: 47.40 (-1.06), ENV: 30.09 (-0.44), LPI: 9.72 (-0.18), GOOG: 625.77 (+4.42), NOW: 73.60 (+0.94), ARMK: 31.69 (+0.43), JAZZ: 160.62 (-0.21), GLF: 7.39 (-0.38), SJW: 28.33 (+0.23), JGW: 5.34 (+0.17), ALCO: 42.01 (+0.80), FI: 16.43 (-0.09), CRM: 70.05 (+0.31)
Opko's Frost Inks Levon Deal with Israel's SciVac, a Hint for the Next Merger?
ACCESSWIRE - Fri Mar 20, 10:30AM CDT
NEW YORK, NY / ACCESSWIRE / March 20, 2015 / On September 11 last year, a little-known Israeli financial magazine called Globes came out with a report that Dr. Phillip Frost, Chairman and CEO of Opko Health (NYSE:OPK), and then Chairman of Teva Pharmaceuticals (NYSE:TEVA), was interested in moving a private Israeli biotech called SciVac, 45% owned by Opko, into a corporate shell and making it public.
OPK: 10.09 (-0.46), TEVA: 63.66 (+1.62)
Cocrystal Pharma announces changes in executive positions
M2 - Fri Mar 13, 7:15AM CDT
Pharmaceutical company Cocrystal Pharma (OTCQB:COCP) reported on Thursday that Dr Gary Wilcox will step down as its chief executive officer due to medical reasons.
Cocrystal Pharma to Appoint Jeffrey Meckler as Interim Chief Executive Officer
Marketwired - Thu Mar 12, 6:30AM CDT
Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, announced today that due to medical reasons, Dr. Gary Wilcox will step down as the current Chief Executive Officer. Mr. Jeffrey Meckler has been appointed as the Interim Chief Executive Officer of the Company effective with the filing of the Form 10-K, later this month. Dr. Wilcox will become the Vice Chairman of the Board of Directors and continue as a senior advisor to the company. Mr. Meckler will continue as a Director of the Company, and Dr. Raymond F. Schinazi will become the Chairman of the Board.
QLTI: 3.44 (unch), OPK: 10.09 (-0.46), PFE: 32.97 (+0.35)
Cocrystal Pharma to Present at Barclays Global Healthcare Conference on Thursday, March 12
Marketwired - Tue Mar 03, 8:24AM CST
Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, announced today that it will present at the Barclays 2015 Global Healthcare Conference on Thursday, March 12, 2015 at 8:00 AM ET at Loews Miami Beach Hotel in Miami, Florida. Dr. Raymond F. Schinazi, co-chairman of the Board of Directors of Cocrystal Pharma, will be presenting on behalf of the Company.
OPK: 10.09 (-0.46)
Nasopharyngitis (Common Cold) - Pipeline Review, H1 2015 - 11 Drug Profiles from 4 Companies
M2 - Mon Mar 02, 8:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/29q354/nasopharyngitis) has announced the addition of the "Nasopharyngitis (Common Cold) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Nasopharyngitis (Common Cold), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nasopharyngitis (Common Cold) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cocrystal Pharma, Inc. - Neos Therapeutics, Inc. - Orbis Biosciences, Inc. - Vernalis plc Drug Profiles - (chlorpheniramine codeine) - Antibody to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - CCP-01 - CCP-05 - CCP-06 - CCP-07 - CCP-08 - guaifenesin ER - Small Molecule for Cough and Cold - Small Molecule to Inhibit MAPK13 for Asthma and Cold - Small Molecules to Inhibit RNA Dependent RNA Polymerase for Common Cold For more information visit http://www.researchandmarkets.com/research/29...haryngitis
